Organigram Holdings Stock Current Asset
| OGI Stock | USD 1.51 0.01 0.67% |
OrganiGram Holdings fundamentals help investors to digest information that contributes to OrganiGram Holdings' financial success or failures. It also enables traders to predict the movement of OrganiGram Stock. The fundamental analysis module provides a way to measure OrganiGram Holdings' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OrganiGram Holdings stock.
The current Non Current Assets Total is estimated to decrease to about 144.2 M. The current Total Current Assets is estimated to decrease to about 119 M. OrganiGram | Current Asset |
OrganiGram Holdings Company Current Asset Analysis
OrganiGram Holdings' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current OrganiGram Holdings Current Asset | 204.52 M |
Most of OrganiGram Holdings' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OrganiGram Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
OrganiGram Current Asset Historical Pattern
Today, most investors in OrganiGram Holdings Stock are looking for potential investment opportunities by analyzing not only static indicators but also various OrganiGram Holdings' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of OrganiGram Holdings current asset as a starting point in their analysis.
OrganiGram Holdings Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
OrganiGram Total Assets
Total Assets |
|
In accordance with the recently published financial statements, OrganiGram Holdings has a Current Asset of 204.52 M. This is 90.5% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current asset for all United States stocks is 97.81% higher than that of the company.
OrganiGram Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OrganiGram Holdings' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OrganiGram Holdings could also be used in its relative valuation, which is a method of valuing OrganiGram Holdings by comparing valuation metrics of similar companies.OrganiGram Holdings is currently under evaluation in current asset category among its peers.
OrganiGram Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of OrganiGram Holdings from analyzing OrganiGram Holdings' financial statements. These drivers represent accounts that assess OrganiGram Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of OrganiGram Holdings' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 792.0M | 286.6M | 865.7M | 438.7M | 394.8M | 278.1M | |
| Enterprise Value | 794.0M | 365.7M | 815.3M | 373.5M | 336.2M | 278.7M |
OrganiGram Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.0556 | ||||
| Profit Margin | (1.54) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 104.95 M | ||||
| Shares Outstanding | 108.57 M | ||||
| Shares Owned By Insiders | 31.32 % | ||||
| Shares Owned By Institutions | 9.71 % | ||||
| Number Of Shares Shorted | 2.75 M | ||||
| Price To Earning | (79.96) X | ||||
| Price To Book | 0.77 X | ||||
| Price To Sales | 1.11 X | ||||
| Revenue | 149.21 M | ||||
| Gross Profit | 35.07 M | ||||
| EBITDA | (25.37 M) | ||||
| Net Income | (229.48 M) | ||||
| Cash And Equivalents | 127.36 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 3.71 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.17 X | ||||
| Book Value Per Share | 2.85 X | ||||
| Cash Flow From Operations | (35.8 M) | ||||
| Short Ratio | 6.16 X | ||||
| Earnings Per Share | (1.79) X | ||||
| Target Price | 8.8 | ||||
| Number Of Employees | 914 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 165.96 M | ||||
| Total Asset | 298.45 M | ||||
| Retained Earnings | (538.53 M) | ||||
| Working Capital | 166.34 M | ||||
| Current Asset | 204.52 M | ||||
| Current Liabilities | 54.43 M | ||||
| Net Asset | 298.45 M |
About OrganiGram Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OrganiGram Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OrganiGram Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OrganiGram Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether OrganiGram Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OrganiGram Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organigram Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organigram Holdings Stock:Check out OrganiGram Holdings Piotroski F Score and OrganiGram Holdings Altman Z Score analysis. For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OrganiGram Holdings. If investors know OrganiGram will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.79) | Revenue Per Share 1.835 | Quarterly Revenue Growth (0.14) | Return On Assets (0.06) | Return On Equity (0.55) |
The market value of OrganiGram Holdings is measured differently than its book value, which is the value of OrganiGram that is recorded on the company's balance sheet. Investors also form their own opinion of OrganiGram Holdings' value that differs from its market value or its book value, called intrinsic value, which is OrganiGram Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OrganiGram Holdings' market value can be influenced by many factors that don't directly affect OrganiGram Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OrganiGram Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if OrganiGram Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OrganiGram Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.